The uptake of innovative advanced treatments in immunology is highly dependent on the indication, with new innovative treatments gaining market share quickly in psoriasis, while older entrenched products still hold considerable market share in psoriatic arthritis.
CRA analytics insight
- 3rd generation biologics (i.e., IL-23 and IL-17A/F products: Skyrizi, Tremfya, Ilumya*, and Bimzelx*) have seen stronger uptake in psoriasis than psoriatic arthritis in recent years
- While 3rd gen biologics account for close to half (45%) of 2023 PsO share, they account for 17% of PsA share, where 1st and 2nd gen biologic use remains strong
CRA not only uncovers new trends in data, but delves deeper to illuminate the “why” behind the findings. To learn more, contact Eddie Li.
